Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, O'Halloran TV.

Angew Chem Int Ed Engl. 2009;48(49):9295-9. doi: 10.1002/anie.200903655. No abstract available.

2.

Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.

Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV.

Mol Cancer Ther. 2009 Jul;8(7):1955-63. doi: 10.1158/1535-7163.MCT-09-0045. Epub 2009 Jun 30.

3.

Triple-negative breast cancer: risk factors to potential targets.

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA.

Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Review.

4.

Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.

Kindler HL, Aklilu M, Nattam S, Vokes EE.

Am J Clin Oncol. 2008 Dec;31(6):553-6. doi: 10.1097/COC.0b013e318178e4cd.

PMID:
19060586
5.

What is the role of arsenic in newly diagnosed APL?

Tallman MS.

Best Pract Res Clin Haematol. 2008 Dec;21(4):659-66. doi: 10.1016/j.beha.2008.09.002. Review.

PMID:
19041605
6.

Nanocarriers as an emerging platform for cancer therapy.

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R.

Nat Nanotechnol. 2007 Dec;2(12):751-60. doi: 10.1038/nnano.2007.387. Review.

PMID:
18654426
7.

Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy.

Yang Z, Yang M, Peng J.

Drug Dev Ind Pharm. 2008 Aug;34(8):834-9. doi: 10.1080/03639040801926733 .

PMID:
18622876
8.

Pharmacokinetics and biodistribution of nanoparticles.

Li SD, Huang L.

Mol Pharm. 2008 Jul-Aug;5(4):496-504. doi: 10.1021/mp800049w. Epub 2008 Jul 9. Review.

PMID:
18611037
9.

Subtypes of breast cancer show preferential site of relapse.

Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW.

Cancer Res. 2008 May 1;68(9):3108-14. doi: 10.1158/0008-5472.CAN-07-5644.

10.

Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.

Bael TE, Peterson BL, Gollob JA.

Melanoma Res. 2008 Apr;18(2):147-51. doi: 10.1097/CMR.0b013e3282f2a7ae.

PMID:
18337652
11.

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.

Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S.

Breast Cancer Res Treat. 2009 Jan;113(2):217-30. doi: 10.1007/s10549-008-9924-5. Epub 2008 Feb 12.

12.
13.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

14.

Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.

Lu J, Chew EH, Holmgren A.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18.

15.

Arsenical-based cancer drugs.

Dilda PJ, Hogg PJ.

Cancer Treat Rev. 2007 Oct;33(6):542-64. Epub 2007 Jul 10. Review.

PMID:
17624680
16.

Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo.

Yu J, Qian H, Li Y, Wang Y, Zhang X, Liang X, Fu M, Lin C.

Gynecol Oncol. 2007 Aug;106(2):400-6. Epub 2007 May 21.

PMID:
17512576
17.

Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.

Berenson JR, Yeh HS.

Clin Lymphoma Myeloma. 2006 Nov;7(3):192-8. Review.

PMID:
17229334
18.

Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release.

Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O'Halloran TV.

J Am Chem Soc. 2006 Oct 18;128(41):13348-9.

PMID:
17031934
19.

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H.

Hematol Oncol. 2006 Dec;24(4):181-8. Review.

PMID:
16783836
20.

Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.

Zhang J, Wang B.

Gynecol Oncol. 2006 Oct;103(1):199-206. Epub 2006 Apr 19.

PMID:
16624393

Supplemental Content

Support Center